UTERUS BODY CANCER



Nume	BER OF CASES PE (2012-2016) ¹	R YEAR	NUMBER OF DEATHS PER YEAR (2012-2016)			
Male	Female	Both sexes	Male	Female	Both sexes	
-	245	-	-	53	-	
FIVE-YEAR SURVIVAL (2006-2010)			24- YEAR PREVALENCE (2016)			
Fi		VAL	24		ENCE	
Fi		VAL Both sexes	24 Male		ENCE Both sexes	

¹ Mean yearly incidence data for period 2012-2016 has been rounded to nearest integer, and thus some numbers in tables will not add to give the exact total.

INCIDENCE

Between 2012 and 2016 there were an average of 245 female patients diagnosed with uterus body cancer each year in Northern Ireland. The probability that a female will develop uterus body cancer before the age of 75 is approximately 1 in 52.


Incidence trends

 Table 1: Incidence of uterus body cancer by year of diagnosis: 2007-2016

	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016
Female	204	223	234	220	227	250	251	232	249	244

Over a ten-year period the number of uterus body cancer cases increased from 204 in 2007 to 244 in 2016. After accounting for population changes, uterus cancer incidence has increased significantly by 3.7% per year until 2009, then decreasing by 0.1%.

Figure 1: Trends in uterus body cancer incidence rates: 1993-2016




2 Uterus body cancer

Incidence and age

Uterus body cancer risk is strongly related to age with 100% of women diagnosed in Northern Ireland over the age of 30 years at the time of diagnosis. Incidence rates are highest among women aged 70-74. Incidence rates decrease thereafter.

There were no reported cases of uterus body cancer in women under the age of 30 in 2012-2016 and incidence remains low until middle age.


Approximately 85% of all cases of uterus body cancer occur between the ages of 45 and 79 with almost one third of all cases diagnosed during the 6th decade of life.



Incidence by Trust area

Uterus body cancer incidence rates in 2012-2016 were significantly lower in the South Eastern Trust area and significantly higher for people living within the Southern Trust compared to the NI average. Incidence rate of 12% below the NI average and 19% above the NI average were recorded respectively compared to other trust areas.

Figure 3: Uterus body cancer incidence rates compared to the NI average by HSC Trust of residence: 2012-2016



Incidence by deprivation

Uterus body cancer incidence is 12% lower among communities within quintile 3 compared to the NI average. However, there appears to be no trend in incidence rates of uterus body cancer and socioeconomic deprivation.





Figure 4: Uterus body cancer incidence rates compared to the NI average by deprivation quintile: 2012-2016

Incidence by stage

Cancer stage is a way of describing the size of a cancer and how far it has grown and spread. This information is important in helping decide what treatments are needed and stage of disease at diagnosis is strongly associated with survival.





Over 90% of uterus body cancer patients were assigned a stage at diagnosis. The majority of uterus body cancer patients were diagnosed at stage I (69.7%). The next most common stage to be diagnosed at was stage III (10.2%).

4 Uterus body cancer

SURVIVAL

The net survival was 90.3% at one year, and 77.6% at five years for patients diagnosed with uterus body cancer in 2006-2010.

Table 2: Five-year uterus body cancer survival by survival time: patients diagnosed 2006-2010

Time since	Diagnosed 2006-2010
diagnosis	Female
6 months	93.7%
1 year	90.3%
5 years	77.6%

Survival Trends

Five-year survival for uterus body cancer has increased in Northern Ireland from the 1993-2000 diagnosis period to the 2006-2010 diagnosis period. Five-year survival between 1993-2000 was 64.7% and 77.6% between 2006-2010 representing a significant increase in survival.

Table 3: Five-year uterus body cancer survival by period of diagnosis


Period of diagnosis	Female
1993-2000	64.7%
2001-2005	69.1%
2006-2010	77.6%

Survival and stage

Stage at diagnosis is one of the most important factors in uterus body cancer survival with fiveyear survival decreasing as stage at diagnosis increases.

Five-year survival ranged from 96.5% for early (stage I) disease to 14.0% for late (stage IV) disease thus highlighting the importance of an early diagnosis.





MORTALITY

In 2012-2016 there were an average of 53 deaths from uterus body cancer each year.

Mortality trends




Figure 7: Trends in uterus body cancer mortality rates: 1993-2016

Over the last ten years the number of uterus body cancer deaths has increased from 33 in 2007 to 57 in 2016. When adjusted for age and population change, uterus body cancer mortality rates increased by approximately +1.6% each year.

PREVALENCE

At the end of 2016 there were 2,564 women living in Northern Ireland who had been diagnosed with uterus body cancer from 1993-2016 (table 4). Of these, almost 10% had been diagnosed in the previous year.

Table 4: Number of people living with uterus body cancer at the end of 2016 who were diagnosed from 1993-2016by time since diagnosis

	Age		Time since	24-year		
Sex		0-1 year	1-5 years	5-10 years	10-24 years	Prevalence
Female	0-69	138	469	362	265	1,242
	70+	87	302	372	569	1,330
	All ages	225	771	734	834	2,572

FURTHER INFORMATION

Further data is available from the Northern Ireland Cancer Registry web site: **www.qub.ac.uk/nicr**

NI Cancer Registry

Phone: +44 (0)28 9097 6028 e-mail: nicr@qub.ac.uk



ACKNOWLEDGEMENTS

NICR is funded by the Public Health Agency and is hosted by Queen's University, Belfast. This work uses data provided by patients and collected by the NHS as part of their care and support.



